PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Affect Disord. Author manuscript; available in PMC May 1, 2012.
Published in final edited form as:
PMCID: PMC3085695
NIHMSID: NIHMS250914
Depression and Eating Disorders: Treatment and Course
David Mischoulon, MD, PhD,1 Kamryn T. Eddy, PhD,2,3 Aparna Keshaviah, ScM,4 Diana Dinescu, BA,2 Stephanie L. Ross, BA,2 Andrea E. Kass, BA,2 Debra L. Franko, PhD,2,5 and David B. Herzog, MD2,3
1Depression Clinical and Research Program, Massachusetts General Hospital, Boston MA 02114, USA
2Harris Center for Education and Advocacy in Eating Disorders, Department of Psychiatry, Massachusetts General Hospital, Boston MA 02114, USA
3Harvard Medical School, Boston MA 02115, USA
4Biostatistics Center, Massachusetts General Hospital, Boston MA 02114, USA
5Department of Counseling and Applied Educational Psychology, Northeastern University, Boston MA 02115, USA
Corresponding Author: David Mischoulon, MD, PhD, 1 Bowdoin Square, 6th Floor, Boston, MA 02114, Tel. 617-724-5198, Fax 617-724-3028, dmischoulon/at/partners.org
Background
We examined the course of major depressive disorder (MDD) and predictors of MDD recovery and relapse in a longitudinal sample of women with eating disorders (ED).
Methods
246 Boston area women with DSM-IV anorexia nervosa-restricting (ANR; n=51), AN-binge/purge (ANBP; n=85), and bulimia nervosa (BN; n=110) were recruited between 1987-1991 and interviewed using the Eating Disorders Longitudinal Interval Follow-up Evaluation (LIFE-EAT-II) every 6-12 months for up to 12 years. 100 participants had MDD at study intake and 45 developed MDD during the study. Psychological functioning and treatment were assessed.
Results
Times to MDD onset (1 week – 4.3 years), recovery (8 weeks – 8.7 years), and relapse (1 week – 5.2 years) varied. 70% recovered from MDD, but 65% subsequently relapsed. ANR patients were significantly less likely to recover from MDD than ANBP patients (p=0.029). Better psychological functioning and history of MDD were associated with higher chance of MDD recovery. Higher baseline depressive severity and full recovery from ED were associated with greater likelihood of MDD relapse; increased weight loss was somewhat protective. Adequate antidepressant treatment was given to 72% of patients with MDD and generally continued after MDD recovery. Time on antidepressants did not predict MDD recovery (p=0.27) or relapse (p=0.26).
Limitations
Small ED diagnostic subgroups; lack of non-ED control group.
Conclusions
The course of MDD in EDs is protracted; MDD recovery may depend on ED type. Antidepressants did not impact likelihood of MDD recovery, nor protect against relapse, which may impact on treatment strategies for comorbid MDD and EDs.
Keywords: Major Depressive Disorder, Eating Disorders, Anorexia Nervosa, Bulimia Nervosa, Antidepressants
Eating disorders (EDs) have high rates of comorbidity with other mental illnesses, especially major depressive disorder (MDD). Multiple studies indicate that MDD is the most common comorbid diagnosis in patients with EDs (Herzog et al. 1992; Fichter & Quadflieg, 2004; Kaye et al. 2008); the American Psychiatric Association has reported that lifetime rates of MDD in individuals with EDs range between 50% and 75% (American Psychiatric Association Workgroup on Eating Disorders, 2006); and MDD comorbid with EDs has been associated with worse ED outcome (Lowe et al. 2001; Berkman et al. 2007), including high rates of suicide attempts (Franko et al. 2004; Bulik et al. 2008; Forcano et al. 2009) and suicide-related mortality (Crow et al. 2009).
Despite the overlap between EDs and depression, FDA-approved antidepressants have not shown promise in alleviating depression in patients with EDs. Although fluoxetine has been approved to treat bulimia nervosa (BN), the drug has shown mixed efficacy in reducing MDD in this group (Pope et al. 1983; Fichter et al. 1991; Fluoxetine Bulimia Nervosa Collaborative Study Group, 1992; Goldbloom & Olmsted, 1993; Beumont et al. 1997; Walsh et al. 1997; Romano et al. 2002). Moreover, antidepressant treatment does not result in improvement in depressive symptomatology in anorexia nervosa (AN) treatment trials (Attia et al. 1998; Walsh et al. 2006). In view of the high rates of suicide and treatment resistance in individuals with comorbid MDD and ED, characterizing the course of MDD and identifying predictors of MDD recovery and relapse in individuals with EDs are important avenues for research.
In 1987 we initiated a prospective longitudinal study of treatment-seeking women with AN and BN to map the course and outcome of EDs. We have previously examined psychiatric comorbidity and found high rates of MDD in this sample (Herzog et al. 1992). Depression severity was associated with increased risk for attempted suicide in AN participants (Franko et al. 2004). By a median of 9 years of follow-up, 11 women had died (Keel et al. 2003). In this study we address the following questions about MDD: (a) What is the course of MDD?; (b) What variables are associated with recovery from and relapse to MDD?; and (c) What types of antidepressant medications do women with EDs receive for MDD and are these treatments adequate by current standards? We hypothesized that the course of MDD would be longer if there was no recovery from ED. Likewise, we expected that women who received antidepressants would be more likely to recover from MDD, even if their ED did not significantly improve.
Participants
Five hundred and fifty-four women who sought treatment at Massachusetts General Hospital and other treatment centers in the Boston area between 1987 and 1990 were screened to determine whether they met criteria for AN or BN set forth in the 3rd Revised Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R; American Psychiatric Association, 1987). Two hundred and twenty-five women originally agreed to participate in the study, and in 1991, 21 additional participants with AN were recruited through Boston-area clinics, increasing the sample size to 246 women. After reclassification into DSM-IV criteria (American Psychiatric Association, 1994), the sample included 51 women with AN-restricting type (ANR), 85 women with AN-binge/purge type (ANBP), and 110 women with BN.
For study inclusion, participants were required to be female, English-speaking, at least 12 years of age, reside within 200 miles of the study site, and meet full criteria for AN or BN. Exclusion criteria were terminal illness or organic brain syndrome. Characteristics of the full sample at intake have been described elsewhere (Herzog et al. 1999). The study was approved by the Institutional Review Board of Massachusetts General Hospital.
Procedure
Following a brief telephone screen, eligible participants were invited for an in-person intake interview during which ED diagnosis was confirmed and psychiatric history obtained. Written informed consent was obtained prior to the interview. Subsequently, participants were interviewed at 6-12 month intervals over a mean and median of 8.6 and 9 years, respectively. All interviews were conducted by a trained research assistant; every attempt was made to conduct follow-up interviews in person; if this was not feasible, follow-up interviews were conducted by phone.
Instruments
Intake
The Schedule for Affective Disorders and Schizophrenia—Lifetime Version (SADS-L, modified version EAT-SADS-L; Spitzer & Endicott, 1979): This semi-structured interview was used to assess current and lifetime comorbid diagnoses.
Beck Depression Inventory (BDI): Participants completed this 21-item self-report measure of behavioral, cognitive, and somatic symptoms of depression (Beck et al. 1961). Higher scores indicate greater symptom severity.
Global Assessment of Functioning (GAF): Research assistants assigned GAF ratings based on Axis V from the DSM (American Psychiatric Association, 1987; American Psychiatric Association, 1994). Scores range from 1-100; higher scores indicate better psychosocial functioning and lower symptom severity.
Follow-up
Eating Disorders Longitudinal Interval Follow-up Evaluation (LIFE-EAT II): The LIFE-EAT II is a semi-structured interview modified from the LIFE II (Keller et al. 1987) that was used to assess eating pathology, comorbid axis I disorders, GAF score, suicidality, and treatment utilization. ED and MDD severity were assessed weekly with a Psychiatric Status Rating (PSR) score (coded 1-6) that corresponded to the Research Diagnostic Criteria (RDC) ratings for the disorders. PSR scores of 1 and 2 indicated no or few symptoms and PSR scores of 5 and 6 equated to full syndrome severity. Body weights were collected via self-report. Therapy (individual, group, and family psychotherapy; psychotropic medication; nutritional counseling; medical management; and hospitalization) was assessed on a week-by-week basis. Further details of the study methodology have been reported elsewhere (Herzog et al. 1999).
Interviewer Training
A 5-step training program modeled after the NIMH Collaborative Psychobiology of Depression Study was used in the training of interviewers. The training program has been described previously (Herzog et al. 1992).
Analysis Population
Of the 246 participants included in the study population, 156 (63%) had lifetime MDD. Eleven of these women had only a history of MDD, with no new episode at study intake or during follow-up. The current report includes the remaining 145 participants (59% of the total study population) who had either MDD at study intake (n=100) or a new onset of MDD during the study (n=45).
Data Analysis
Outcome variables
MDD was diagnosed according to the RDC on the basis of the EAT-SADS-L interview at study intake and the LIFE-EAT II interview during follow-up. Outcome variables analyzed were time to first MDD recovery and time to first MDD relapse. Patients were considered to have recovered from MDD if they had an MDD PSR score ≤2 for at least 8 consecutive weeks. Patients were considered to have relapsed to MDD if they had an MDD PSR score ≥5 at any time.
Predictor variables
A number of fixed and time-varying covariates were examined as predictors of MDD recovery and relapse. Fixed covariates included: intake ED diagnosis (ANR/ANBP/BN); duration (years) of ED illness prior to study intake; percent of ideal body weight (IBW) at study intake; history of suicide gestures or attempts (Yes/No) at study intake; history of MDD before entry into the study (Yes/No); current MDD at study intake (Yes/No); lifetime drug use disorder at study intake (Yes/No); lifetime alcohol use disorder at study intake (Yes/No); BDI score; and age at study intake; and total weeks of individual psychotherapy.
Time-varying covariates were assessed every week (except as noted) on the basis of the follow-up LIFE-EAT II data, and included: ED PSR scores; on-study ED diagnosis (see next paragraph); weight loss (ordinal categories representing percent below IBW: 6-9%/10-14%/15-20%/21-29%/30-39%/≥40%); suicide gestures or attempts (Yes/No, assessed monthly and transformed to weekly measurements by assuming constancy over the month); binge eating (Yes/No); purging (Yes/No); compensatory fasting or vigorous exercise (Yes/No); weeks of adequate antidepressant treatment, defined as ≥6 consecutive weeks of treatment at the recommended dosage for that particular antidepressant (defined as a dose greater than or equal to a dose usually considered effective, e.g. ≥20mg/day of fluoxetine); weeks of therapy (as described above, including both a Yes/No covariate and cumulative number of weeks received); and GAF score (assessed monthly and transformed to weekly measurements by assuming constancy over the month).
Time-varying on-study ED diagnosis was defined using the maximum AN and BN PSR scores achieved over a 13 week period (i.e., 3 months). ANR diagnosis required an AN PSR score ≥5 and a BN PSR score ≤2; ANBP diagnosis required an AN PSR score ≥5 and a BN PSR score ≥3; and BN diagnosis required a BN PSR score ≥5 and an AN PSR ≤4. Full recovery required both AN and BN PSR scores ≤2.
Statistical methods
Cox Proportional Hazards (PH) regression was used to identify predictors of MDD recovery and of MDD relapse. To conserve power, univariate analyses were first conducted at the alpha=0.05 level. Significant covariates were then entered into multivariate models, with automated stepwise selection (alpha=0.15 to enter, alpha=0.10 to stay) used to identify a parsimonious model. Finally, interactions between the (marginally) significant predictors were tested individually at the alpha=0.10 level. Descriptive Kaplan-Meier plots of time to MDD recovery and MDD relapse were also generated. No adjustments were made for multiple comparisons to ensure that potential drivers of MDD recovery and relapse are not obscured in this initial investigation, and because a universal null hypothesis does not exist in this context (Rothman, 1990).
For all time-varying covariates, a lag of 1 week was applied in the Cox PH models to strengthen the case for causality – i.e. at any time point, MDD recovery/relapse was predicted based on patients’ covariate values 1 week prior to that time point. Additional lags were investigated, but did not alter the results.
Analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC).
Of the 145 patients with MDD included in the analysis, 102 (70%) recovered from MDD over the course of the study, but 66 (65%) of these 102 patients subsequently relapsed to MDD. The mean and median follow-up time for the analysis population was 8.8 and 10.0 years, respectively (range = 3 months-12 years). Time from MDD onset to recovery (8 weeks–8.7 years) and time from MDD recovery to relapse (1 week–5.2 years) varied greatly, as did time from study entry to new onset of MDD (1 week–4.3 years) for patients without MDD at study intake. Of the 102 patients recovered from MDD, 9 (9%) had previously fully recovered from their ED. By comparison, among the 43 patients who did not recover from MDD, 16 (37%) had previously fully recovered from their ED. Table 1 presents additional descriptive statistics for the analysis population as a whole, and separately for those who recovered from and relapsed to MDD.
Table 1
Table 1
Descriptive Characteristics of Analysis Population
Predictors of Recovery from MDD
In univariate analyses, significant predictors of MDD recovery included history of MDD, BDI score, and GAF score (Table 2). Patients with a history of MDD, less severe depression (i.e., lower BDI score), and better psychological functioning (i.e., higher GAF score) were more likely to recover from depression. Intake ED diagnosis was a marginally significant predictor (p=0.085), with ANR patients significantly less likely to recover from MDD than ANBP (p=0.029) or BN (p=0.052) patients.
Table 2
Table 2
(Marginally) Significant Predictors of MDD Recovery based on Cox PH Regression
After multivariate stepwise selection, BDI and GAF remained significant predictors (Figure 1 A,B), but history of MDD was no longer significant. The effect of GAF on MDD recovery varied by MDD history (p=0.0021). After controlling for BDI score, a 2-point increase in GAF score led to an 11% greater likelihood of MDD recovery overall (results not shown). But for patients without a history of MDD, a 2-point increase in GAF score led to a 23% greater likelihood of MDD recovery, (Table 2). Total number of weeks of individual therapy (as a fixed covariate) was a non-significant predictor of MDD recovery (p=0.93).
Figure 1
Figure 1
Time to MDD Recovery / Relapse by Significant Predictors in Multivariate Models
Predictors of Relapse to MDD
BDI score was the only significant predictor of MDD relapse univariately. Patients with more severe depression at baseline had the highest likelihood of MDD relapse (Table 3). Weeks of individual psychotherapy, time-varying weight loss and time-varying on-study ED diagnosis were borderline significant, with patients most at risk of relapsing being those who received more psychotherapy, were closer to their ideal body weight, and fully recovered from their ED. After multivariate stepwise selection, BDI score and time-varying weight loss were both significant at the alpha=0.10 level (Figure 1 C,D), but neither weeks of psychotherapy nor time-varying ED diagnosis remained significant. The effect of BDI on MDD relapse varied by on-study ED diagnosis (p=0.011). After controlling for weight loss, a 5-point increase in BDI score led to a 22% greater likelihood of MDD relapse overall (results not shown). But for patients who had fully recovered from their ED, a 5-point increase in BDI score led to a 43% greater likelihood of MDD relapse (Table 3).
Table 3
Table 3
(Marginally) Significant Predictors of MDD Relapse based on Cox PH Regression
Treatment of MDD in the Sample
With regard to antidepressant treatment in the participants with MDD, most patients (72%) were found to have received adequate antidepressant treatment at some point during the study, though a few received inadequate treatment, and almost one-fifth went untreated (Table 1). Forty (28%) of the 145 MDD patients received at least 60 mg of fluoxetine at some time point during the study; another 9 patients (6%) received an unknown dosage that could have been as high as 60mg. About 90% of patients received therapy of some type, and 83% received individual psychotherapy (at 79% of weeks during which some form of therapy was administered). Over the course of follow-up, adequate antidepressant treatment was administered to 75% of patients who recovered from MDD and to 85% of patients who subsequently relapsed (Table 1).
Figure 2 graphs the percentage of weeks (per 6-month interval) in which different combinations of psychotherapy and/or antidepressant treatment were administered, separately for participants who did not recover from MDD (A), did recover from MDD (B), and recovered but subsequently relapsed to MDD (C). For example, Figure 2A shows that among patients who did not recover from MDD, antidepressants plus psychotherapy were administered at 13% of weeks, psychotherapy alone was administered at 65% of weeks, anti-depressants alone were administered at 0% of weeks, and no/inadequate therapy was administered in 22% of weeks during the first 6 months of the study. Panel B illustrates that treatment was not stopped once a participant recovered from MDD. On the contrary, among the 77 patients who received adequate treatment with antidepressants and recovered from MDD, 54 (96%) of the 56 who subsequently relapsed continued to receive antidepressant treatment after MDD recovery, as did 16 (76%) of the 21 who did not subsequently relapse.
Figure 2
Figure 2
Utilization Of Anti-Depressants And Psychotherapy Over Time
Despite the fact that individuals in this study by and large received adequate antidepressant treatment, total weeks of antidepressant treatment was neither a significant predictor of MDD recovery (p=0.27) nor of MDD relapse (p=0.26). To test the robustness of our findings and ensure that lack of significance was not specific to how the covariate was defined in the model, antidepressant treatment was modeled a number of ways, including: total weeks of treatment; any treatment received (Yes/No); and adequate/inadequate/no treatment received. Fluoxetine alone was also isolated, since it was the most commonly prescribed antidepressant (given to 87% of patients who were treated with an antidepressant, and administered at 49% of weeks in which an antidepressant was administered). Finally, we examined the effect of treatment after controlling for time-varying weight loss, and also within time-varying on-study ED categories, to see if the overall effect of antidepressant treatment was obscured by confounding or effect modification. Regardless of how treatment was modeled in our analyses, it did not significantly affect the likelihood of MDD recovery or relapse in this population.
To our knowledge, this is the first prospective investigation of the course of MDD in an ED sample, derived from the largest and longest prospective, naturalistic longitudinal follow-up of women with EDs. Consistent with previous reports of MDD in ED samples (Brewerton et al. 1995; Godart et al. 2004; Fernandez-Aranda et al. 2007; Herzog & Eddy, 2007), we found that 59% of the 246 patients recruited had one or more episodes of depression, a prevalence much greater than the 15% or so that would be expected in the general population.
With regard to MDD recovery and relapse, patients who fared the worst had more severe baseline depressive symptoms, and better psychological functioning suggested a higher chance of recovery. Our findings are consistent with previous studies of depression that have linked more severe depressive symptoms to poorer treatment outcomes (Kirsch et al. 2008).
Rates of MDD recovery varied by ED diagnosis at study entry, with patients diagnosed as ANR having a lower chance of recovery from MDD than those diagnosed with ANBP or BN. However, participants with ANR who did recover from MDD were less likely to have had an MDD relapse compared to individuals who had fully recovered from their ED. Likewise, participants were more likely to have a depressive relapse if they were closer to their ideal body weight. This finding is consistent with previous studies that indicate that recovered or weight-restored AN participants continue to experience increased or persistent depressive symptomatology in comparison to healthy controls (Pollice et al. 1997; Holtkamp et al. 2005; Wagner et al. 2006).
These findings were striking, as it is generally thought that recovery from one condition may facilitate recovery from a comorbid condition. There may, however, be other factors in play with regard to patients with EDs. For example, recovering from an ED and/or attaining a healthier weight may mobilize control issues within the patient, which may in turn precipitate feelings of depression. Recovery from an ED may be associated with a loss of identity and routine, and fuel a fear of weight gain. Beresin et al. (1989) interviewed women who had recovered from AN who reported that with their recovery, they initially felt a loss of self-respect (for “giving in” to getting well) and that they were losing their ‘specialness’. Such feelings may lead to depressive symptoms, particularly if the ED is chronic.
Lifetime alcohol and drug abuse were relatively uncommon in the sample as a whole (17% and 14%, respectively; Table 1), and rates did not change significantly in the recovered and relapsed samples. We do not have information on whether the history of alcohol or substance abuse represented current or past abuse in these subjects, but the findings suggest that a lifetime history of these did not significantly impact on recovery or relapse from MDD. Consistent with recent reports (Steffen et al. 2006), our primary and sensitivity analyses revealed antidepressant treatment did not significantly impact either recovery from or relapse to MDD. This may reflect the increasingly questionable efficacy of antidepressants in general (Moncrieff et al. 2004), or a finding specific to an ED population in which greater comorbidity may lead to poorer outcomes. It is also possible that participants may not have been compliant in taking the medication, or that the medications may not have been absorbed due to purging behaviors.
Limitations of this study warrant acknowledgement. The ED diagnostic subgroups in our study were small, and ideally this study should be replicated in a larger sample with all diagnostic subgroups. Our study also lacked a control group of participants without EDs, and thus we cannot attribute effects observed specifically to the presence of an eating disorder, nor rule out the confounding effect of time in this longitudinal study.
This study was initiated in 1987 and we used RDC criteria for MDD because of the consideration regarding its stability over time. The DSM is now used for research and clinical work on MDD, and diagnostic instruments have been modified for the updated criteria. During the study period, selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine, were the most commonly prescribed medications for depression, and thus it may be difficult to generalize these findings to the larger range of antidepressants currently available. It was difficult to determine whether any improvements seen among ED subjects were due to either anti-depressants or to psychotherapy, since most patients received both, and only 9 patients (6%) received antidepressants alone at some point in the course of the study. Also, data were available only for treatment received, and not the specific reason for treatment. Finally, because there was no accepted therapy for AN or BN at the time, we did not gather details about psychotherapy administered. It is possible that cognitive behavioral therapy (often the initial treatment of choice for BN now) may have had an impact on MDD symptoms.
In conclusion, our findings support an overlap between EDs and MDD, and suggest that the presence and type of ED may affect recovery from MDD and relapse to MDD. While these findings may suggest a relationship between EDs and MDD, they do not demonstrate any specific causal link. Antidepressants do not seem to significantly impact MDD recovery or relapse in this population, which may have implications for the development of treatment strategies in individuals with comorbid MDD and EDs.
Acknowledgments
None to report
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  • American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Third Edition. APA Press; Washington, DC: 1987. Revised.
  • American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition APA Press; Washington, DC: 1994.
  • American Psychiatric Association Workgroup on Eating Disorders Practice Guideline for the treatment of patients with eating disorders (revision) American Journal of Psychiatry. 2006;163:1–39. [PubMed]
  • Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the impatient treatment of anorexia nervosa? American Journal of Psychiatry. 1998;155:548–551. [PubMed]
  • Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:561–571. [PubMed]
  • Beresin EV, Gordon C, Herzog DB. The process of recovering from anorexia nervosa. Journal of the American Academy of Psychoanalysis. 1989;17:103–130. [PubMed]
  • Berkman ND, Lohr KN, Bulik CM. Outcomes of eating disorders: a systematic review of the literature. International Journal of Eating Disorders. 2007;40:293–309. [PubMed]
  • Beumont PJ, Russell JD, Touyz SW, Buckley C, Lowinger K, Talbot P, Johnson GF. Intensive nutritional counseling in bulimia nervosa: a role for supplementation with fluoxetine? Australian and New Zealand Journal of Psychiatry. 1997;31:514–524. [PubMed]
  • Brewerton TD, Lydiard RB, Herzog DB, Brotman AW, O’Neil PM, Ballenger JC. Comorbidity of axis I psychiatric disorders in bulimia nervosa. Journal of Clinical Psychiatry. 1995;56:77–80. [PubMed]
  • Bulik CM, Thornton L, Pinheiro AP, Plotnicov K, Klump KL, Brandt H, Crawford S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, Mitchell J, Nutzinger D, Strober M, Treasure J, Woodside DB, Berrettini WH, Kaye WH. Suicide attempts in anorexia nervosa. Psychosomatic Medicine. 2008;70:378–383. [PubMed]
  • Crow SJ, Peterson CB, Swanson SA, Raymond NC, Specker S, Eckert ED, Mitchell JE. Increased mortality in bulimia nervosa and other eating disorders. American Journal of Psychiatry. 2009;166:1342–1346. [PubMed]
  • Fernandez-Aranda F, Pinheiro AP, Tozzi F, Thornton LM, Fichter MM, Halmi KA, Kaplan AS, Klump KL, Strober M, Woodside DB, Crow S, Mitchell J, Rotondo A, Keel P, Plotnicov KH, Berrettini WH, Kaye WH, Crawford SF, Johnson C, Brandt H, La Via M, Bulik CM. Symptom profile of major depressive disorder in women with eating disorders. Australian and New Zealand Journal of Psychiatry. 2007;41:24–31. [PubMed]
  • Fichter MM, Leibl K, Rief W, Brunner E, Schmidt-Auberger S, Engel RR. Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry. 1991;24:1–7. [PubMed]
  • Fichter MM, Quadflieg N. Twelve-year course and outcome of bulimia nervosa. Psychological Medicine. 2004;34:1395–1406. [PubMed]
  • Fluoxetine Bulimia Nervosa Collaborative Study Group Fluoxetine in the Treatment of Bulimia Nervosa. Archives of General Psychiatry. 1992;49:139–147. [PubMed]
  • Forcano L, Fernandez-Aranda F, Alvarez-Moya E, Bulik C, Granero R, Gratacos M, Jimenez-Murcia S, Krug I, Mercader JM, Riesco N, Saus E, Santamaria JJ, Estivill X. Suicide attempts in bulimia nervosa: personality and psychopathological correlates. European Psychiatry. 2009;24:91–97. [PubMed]
  • Franko DL, Keel PK, Dorer DJ, Blais MA, Delinsky SS, Eddy KT, Charat V, Renn R, Herzog DB. What predicts suicide attempts in women with eating disorders? Psychological Medicine. 2004;34:843–853. [PubMed]
  • Godart NT, Perdereau F, Curt F, Lang F, Venisse JL, Halfon O, Bizouard P, Loas G, Corcos M, Jeammet P, Flament MF. Predictive factors of social disability in anorexic and bulimic patients. Eating and Weight Disorders. 2004;9:249–257. [PubMed]
  • Goldbloom DS, Olmsted MP. Pharmacotherapy of bulimia nervosa with fluoxetine: Assessment of clinically significant attitudinal change. American Journal of Psychiatry. 1993;150:770–774. [PubMed]
  • Herzog DB, Dorer DJ, Keel PK, Selwyn SE, Ekeblad ER, Flores AT, Greenwood DN, Burwell RA, Keller MB. Recovery and relapse in anorexia and bulimia nervosa: A 7.5-year follow-up study. Journal of the American Academy of Child & Adolescent Psychiatry. 1999;38:829–837. [PubMed]
  • Herzog DB, Eddy KT. Psychiatric comorbidity in eating disorders. In: Wonderlich S, Mitchell J, de Zwaan M, Steiger H, editors. Annual Review of Eating Disorders, Part I. Radcliffe Publishing; Oxford: 2007. pp. 35–50.
  • Herzog DB, Keller MB, Sacks NR, Yeh CJ, Lavori PW. Psychiatric comorbidity in treatment-seeking anorexics and bulimics. Journal of the American Academy of Child & Adolescent Psychiatry. 1992;31:810–818. [PubMed]
  • Holtkamp K, Müller B, Heussen N, Remschmidt H, Herpertz-Dahlmann B. Depression, anxiety, and obsessionality in long-term recovered patients with adolescent-onset anorexia nervosa. European Child & Adolescent Psychiatry. 2005;14:106–10. [PubMed]
  • Kaye WH, Bulik CM, Plotnicov K, Thornton L, Devlin B, Fichter MM, Treasure J, Kaplan A, Woodside DB, Johnson CL, Halmi K, Brandt HA, Crawford S, Mitchell JE, Strober M, Berrettini W, Jones I. The genetics of anorexia collaborative study: methods and sample description. International Journal of Eating Disorders. 2008;41:289–300. [PubMed]
  • Keel PK, Dorer DJ, Eddy KT, Franko DL, Charatan DL, Herzog DB. Predictors of mortality in eating disorders. Archives of General Psychiatry. 2003;60:179–183. [PubMed]
  • Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC. The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Archives of General Psychiatry. 1987;44:540–548. [PubMed]
  • Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine. 2008;5(2):e45. [PMC free article] [PubMed]
  • Lowe B, Zipfel S, Bucholz C, Dupont Y, Reas DL, Herzog W. Long-term outcome of anorexia nervosa in a prospective 21-year follow-up study. Psychological Medicine. 2001;31:881–890. [PubMed]
  • Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews. 2004;(1) CD003012. [PubMed]
  • Pollice C, Kaye WH, Greeno CG, Weltzin TE. Relationship of depression, anxiety, and obsessionality to state of illness in anorexia nervosa. International Journal of Eating Disorders. 1997;21:367–76. [PubMed]
  • Pope HG, Hudson JI, Jonas JM, Jurgelun-Todd D. Bulimia treated with imipramine: a placebo-controlled, double-blind study. American Journal of Psychiatry. 1983;140:554–558. [PubMed]
  • Romano SJ, Halmi KA, Sarkar NP, Koke SC, Lee JS. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. American Journal of Psychiatry. 2002;159:96–102. [PubMed]
  • Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–46. [PubMed]
  • Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia Lifetime Version. New York State Psychiatric Institute. Biometrics Research; New York: 1979.
  • Steffen KJ, Roerig JL, Mitchell JE, Uppala S. Emerging drugs for eating disorder treatment. Expert Opinion on Emerging Drugs. 2006;11:315–336. [PubMed]
  • Wagner A, Barbarich-Marsteller NC, Frank GK, Bailer UF, Wonderlich SA, Crosby RD, Henry SE, Vogel V, Plotnicov K, McConaha C, Kaye WH. Personality traits after recovery from eating disorders: do subtypes differ? International Journal of Eating Disorders. 2006;39:276–84. [PubMed]
  • Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, Pike KM, Devlin MJ, Woodside B, Roberto CA, Rockert W. Fluoxetine after weight restoration in anorexia nervosa: A randomized controlled trial. Journal of the American Medical Association. 2006;295:2605–2612. [PubMed]
  • Walsh BT, Wilson GT, Loeb KL, Devlin MJ, Pike KM, Roose SP, Fleiss J, Waternaux C. Medication and psychotherapy in the treatment of bulimia nervosa. American Journal of Psychiatry. 1997;154:523–531. [PubMed]